Q-BIOLOGICALS NV - Belgium 
Ranking results:
Past rankings:
| 2013 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | 400-500 |
| Total Project Funding per Partner: | 300-400 |
| Total Number of Projects: | 69 |
| Total Project Funding: | 400-500 |
| Partner Constancy: | 58 |
| Project Leadership Index: | 69 |
| Diversity Index: | 17 |
Ranking timeline:
Project Participation Performance(2013-01-01 - 2024-12-31 ):
Total Project Funding:
Funding per Partner:
Projects:
Leadership:
Total number of projects: 6
As coordinator: 0
As participant: 6
Sole participant: 0
Coordinator / Participant Ratio: 0*
Summary:
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2016 | 0 | 21.000.000 | 175.097 | 1 | ||
| 2013 | 0 | 26.924.619 | 4.561.271 | 5 | ||
Networking:
Partners:
Constancy:
Total number of partners: 63
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 63
Frequent / Rare Partner Ratio: 0
Project overview:
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2016-03-01 | PERtussIS COrrelates of Protection Europe - Sofia ref.: 115910 | PERISCOPE | participant | 21.000.000 | 24 |
| 2013-12-01 | Rewiring the Streptomyces cell factory for cost-effective production of biomolecules | STREPSYNTH | participant | 8.691.070 | 16 |
| 2013-10-01 | Clinical development of TA-101 for the treatment of rheumatoid arthritis | TA101-GOCLIN | participant | 1.357.928 | 7 |
| 2013-10-01 | "Developing and Testing a novel, low-cost, effective HOOKworm VACcine to Control Human Hookworm Infection in endemic countries" | HOOKVAC | participant | 5.999.983 | 9 |
| 2013-10-01 | InFLUenza virus UNIVersal VACcine development program | FLUNIVAC | participant | 5.066.881 | 8 |
| 2013-06-01 | Oral Vaccination against Clostridium difficile Infection | CDVAX | participant | 5.808.757 | 5 |